Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03459729 · ClinicalTrials.gov registry record · Early Phase 1
Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer
A Early Phase 1 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT03459729 is a Early Phase 1 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 6 participants.
The verdict
NCT03459729, a Early Phase 1 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
A Window of Opportunity Clinical Trial. This study design permits examination of effects of an oral agent on cancer patients during the "window" between diagnosis of their cancer and their definitive cancer surgery. Similar to a phase 0 study, the trial design permits examination of the biologic effects of an agent; in this study pharmacokinetic properties will be examined.
Interventions
- DRUG Antitumor B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-08-24 |
| Est. Completion | 2022-02-16 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03459729
The ClinicalTrials.gov registry entry for NCT03459729 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Antitumor B is the first listed.
NCT03459729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03459729 about?
NCT03459729 is a clinical study titled "Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer". A Window of Opportunity Clinical Trial. This study design permits examination of effects of an oral agent on cancer patients during the "window" between diagnosis of their cancer and their definitive cancer surgery. Similar to a phase 0 study, the trial design permits examination of the biologic eff...
What is the current status of trial NCT03459729?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2021-08-24. Estimated completion is 2022-02-16.
What interventions are being tested in trial NCT03459729?
The interventions under investigation include: Antitumor B (DRUG).
Who is sponsoring clinical trial NCT03459729?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.